Prudentia Sciences is an innovative healthcare startup focused on redefining biopharma asset identification, diligence, and valuation. The company aims to build a drug asset marketplace of the future by empowering biopharma organizations to accelerate drug pipelines, optimize returns on investment, and improve clinical and commercial success for enhanced patient impact. Prudentia offers an AI-powered platform that provides asset diligence and valuation tools to de-risk investments in drug development. Key offerings include real-time data-driven simulations, AI-guided product profiles, and expert analytics for portfolio optimization. Their technology is designed to help decision-makers reduce risks, make informed investments, and enhance deal throughput in the competitive life sciences market.